Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Metrics to compare | B8Fk | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipB8FkPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −0.1x | −0.5x | |
PEG Ratio | 0.01 | 0.01 | 0.00 | |
Price / Book | 0.8x | 0.5x | 2.6x | |
Price / LTM Sales | 0.7x | 2.5x | 2.9x | |
Upside (Analyst Target) | - | 27.2% | 64.0% | |
Fair Value Upside | Unlock | 13.6% | 9.4% | Unlock |